Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

FDA Approves Tremfya (Guselkumab) for Adult Patients with Psoriatic Arthritis

  |  

HORSHAM, PA—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)…

Some Drug Trials Resume after Declines During Pandemic

Michael Erman & Carl O'Donnell  |  

(Reuters)—Pharmaceutical companies have ramped up clinical trials in the past month, rebounding from a steep decline in activity following the start of the COVID-19 outbreak, though activity remains below pre-pandemic levels, according to new research shareS with Reuters. The research, which was prepared by clinical trial consulting firm Medidata, shows that new subjects entered trials…

With Apps & Remote Medicine, Japan Offers Glimpse of Doctor Visits in Post-COVID-19 Era

Kaori Kaneko & Izumi Nakagawa  |  

TOKYO (Reuters)—The coronavirus crisis has prompted Japan to ease regulations on remote medical treatment, creating an opening for tech companies and offering a glimpse of the future of healthcare in the world’s most rapidly aging society. As coronavirus cases spiked in April, Japan temporarily eased restrictions on remote medical care, allowing doctors to conduct first-time…

Caring for Pediatric Patients During a Pandemic: Q&A with Jay Mehta, MD

  |  

Caring for pediatric patients during a pandemicin the age of COVID-19 requires adaptations, says Jay Mehta, MD, Children’s Hospital of Philadelphia. “The one exposure that seems to put [pediatric] patients at risk is if they are on higher doses of steroids, with some data suggesting worse outcomes. We just put out guidelines telling providers to reduce steroids in their patients to the lowest dose that can adequately control their disease.”